Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2017 | 1 |
2020 | 3 |
2021 | 2 |
2024 | 0 |
Search Results
4 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies.
Semin Hematol. 2021 Jan;58(1):35-44. doi: 10.1053/j.seminhematol.2020.11.008. Epub 2020 Dec 14.
Semin Hematol. 2021.
PMID: 33509441
Free PMC article.
Clinical Trial.
A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic cancer.
Sohal D, Krishnamurthi S, Tohme R, Gu X, Lindner D, Landowski TH, Pink J, Radivoyevitch T, Fada S, Lee Z, Shepard D, Khorana A, Saunthararajah Y.
Sohal D, et al. Among authors: fada s.
Am J Cancer Res. 2020 Sep 1;10(9):3047-3060. eCollection 2020.
Am J Cancer Res. 2020.
PMID: 33042633
Free PMC article.
Item in Clipboard
Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.
Molokie R, Lavelle D, Gowhari M, Pacini M, Krauz L, Hassan J, Ibanez V, Ruiz MA, Ng KP, Woost P, Radivoyevitch T, Pacelli D, Fada S, Rump M, Hsieh M, Tisdale JF, Jacobberger J, Phelps M, Engel JD, Saraf S, Hsu LL, Gordeuk V, DeSimone J, Saunthararajah Y.
Molokie R, et al. Among authors: fada s.
PLoS Med. 2017 Sep 7;14(9):e1002382. doi: 10.1371/journal.pmed.1002382. eCollection 2017 Sep.
PLoS Med. 2017.
PMID: 28880867
Free PMC article.
Clinical Trial.
Item in Clipboard
DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.
Khouri J, Faiman BM, Grabowski D, Mahfouz RZ, Khan SN, Wei W, Valent J, Dean R, Samaras C, Jha BK, Lazarus H, Campagnaro EL, Malek E, Reed J, Karam MA, Hamilton K, Fada S, Kalaycio M, Liu H, Sobecks R, Saunthararajah Y, Chew Y, Orloff M, Reu FJ.
Khouri J, et al. Among authors: fada s.
Semin Hematol. 2021 Jan;58(1):45-55. doi: 10.1053/j.seminhematol.2020.12.004. Epub 2020 Dec 28.
Semin Hematol. 2021.
PMID: 33509443
Clinical Trial.
Item in Clipboard
Cite
Cite